Diversified Trust Co Trims Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Diversified Trust Co decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,922 shares of the medical research company’s stock after selling 79 shares during the quarter. Diversified Trust Co’s holdings in IQVIA were worth $574,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in IQV. Canada Pension Plan Investment Board grew its position in shares of IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after acquiring an additional 211,653 shares during the period. Farallon Capital Management LLC grew its holdings in IQVIA by 3.1% during the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after purchasing an additional 86,870 shares during the period. FMR LLC increased its position in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares during the period. Finally, Impax Asset Management Group plc lifted its position in shares of IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after buying an additional 157,809 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Down 0.2 %

Shares of IQV stock opened at $203.83 on Friday. The company has a market cap of $37.00 billion, a PE ratio of 26.75, a price-to-earnings-growth ratio of 2.05 and a beta of 1.48. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The stock’s 50 day simple moving average is $201.84 and its two-hundred day simple moving average is $221.62. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Analysts Set New Price Targets

A number of equities research analysts have commented on IQV shares. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Redburn Atlantic initiated coverage on IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price target for the company. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Wednesday, December 11th. Finally, Barclays cut their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $255.82.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.